GE Healthcare has signed a research agreement with Brigham and Women’s Hospital (BWH), a 777-bed teaching affiliate of Harvard Medical School, to establish an alliance in medical research in area of Positron Emission Tomography (PET). The agreement is expected to leverage GE Healthcare’s Molecular Imaging (MI) research efforts, quickly transitioning those discoveries into the clinical environment.
“Collaborations of this caliber are direct investments in the future of healthcare,” said Terri Bresenham, vice president of the GE Healthcare Molecular Imaging business. “Brigham and Women’s world-class patient care, in conjunction with their stellar research and clinical-trial track record, make them an optimal partner in discovering new MI technologies to diagnose and treat disease.”
Clinicians and scientists from both BWH and GE Healthcare plan to use the tools of molecular imaging and radiopharmaceutical development to further the cause of developing personalized approaches to the diagnosis and management of patients with oncologic, neurologic and cardiovascular diseases.
“The collaboration of GE Health Care’s resources in chemistry, biology, drug development, engineering and imaging technology with BWH strengths in clinical research create a partnership with unlimited potential to improve the care of patients,” said Steven Seltzer, managing director, chairman, Department of Radiology at BWH.
“The more we understand about disease from a clinical standpoint, the better equipped we are to build technologies to improve patient care,” said Jean-Luc Vanderheyden, GE Healthcare’s Global Molecular Imaging Leader. “This collaboration has the ability accelerate the process of developing more effective methods of diagnosing, treating and monitoring disease.”